|
業務類別
|
Biotechnology |
|
業務概覽
|
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics. |
| 公司地址
| 200 Talcott Avenue, 2nd Floor, Watertown, MA, USA, 02472 |
| 電話號碼
| +1 617 952-0555 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.werewolftx.com |
| 員工數量
| 39 |
| Mr. Michael Urban |
Vice President of Finance,Corporate Controller and Chief Financial Officer |
-- |
13/02/2026 |
| Dr. Daniel J. Hicklin,, PhD |
Director, President and Chief Executive Officer |
美元 608.24K |
27/03/2026 |
| Dr. Chulani Karunatilake, PhD |
Chief Technology Officer |
-- |
28/04/2025 |
| Mr. Steven Bloom |
Chief Business Officer |
-- |
27/03/2026 |
|
|
| Dr. Luke B. Evnin,PhD |
Chairman of the Board |
27/03/2026 |
| Dr. Michael B. Atkins, M.D. |
Director |
27/03/2026 |
| Mr. Michael A. Sherman, M.B.A. |
Independent Director |
27/03/2026 |
| Dr. Briggs W. Morrison, M.D. |
Director |
27/03/2026 |
| Dr. Meeta Chatterjee, PhD |
Independent Director |
27/03/2026 |
| Dr. Daniel J. Hicklin,, PhD |
Director, President and Chief Executive Officer |
27/03/2026 |
| Dr. Anil K. Singhal, PhD |
Director |
27/03/2026 |
|
|
|
|
